Literature DB >> 10573073

Microangiopathy in kidney and simultaneous pancreas/kidney recipients treated with tacrolimus: evidence of endothelin and cytokine involvement.

G W Burke1, G Ciancio, R Cirocco, M Markou, L Olson, N Contreras, D Roth, V Esquenazi, A Tzakis, J Miller.   

Abstract

BACKGROUND: In the past 3 years, three transplant recipients [one kidney, two simultaneous pancreas/kidney (SPK)] developed a thrombotic thrombocytopenic purpura-like clinical syndrome. This was characterized by an abrupt fall in the hematocrit and platelet count with evidence of hemolysis (fragmented red blood cells and schistocytes) and transplant kidney dysfunction during the first 2 weeks after transplantation. This was also associated with pancreatic dysfunction in the two SPK recipients. In all three patients, elevated tacrolimus levels (>24 ng/ml) occurred.
METHODS: Serum cytokine and endothelin levels were determined retrospectively from stored (-70 degrees C) sera.
RESULTS: In each case tacrolimus was discontinued, and treatment with plasmapheresis, fresh frozen plasma, steroids, and OKT3 was begun. The clinical courses varied from mild (one patient), to moderate (one patient), to severe (one patient), complicated with seizures and coma. Each patient responded clinically and ultimately was converted to cyclosporine A, and/or mycophenolate mofetil. These clinical events were associated with a rise in serum levels of endothelin and several cytokines. Levels of endothelin were elevated at 209+/-137 pg/ml, particularly in the severe episode where peak levels reached 480 pg/ml (normal 0-20 pg/ml). Peak levels of IL-8 (104+/-36 pg/ml), interleukin- (IL) 10 (238+/-105 pg/ml), and/or IL-12 (306+/-119 pg(ml) mean+/-SE, occurred during or before the clinical event. Serum levels of tumor necrosis factor-a and interferon-gamma were elevated in 2 patients while levels of IL-2, IL-4, and IL-6 were not elevated during the acute phase.
CONCLUSIONS: These data are consistent with a mechanism of microangiopathy involving endothelial cell injury (associated with tacrolimus treatment), and accompanied by cytokines (IL-10, IL-12, tumor necrosis factor-a, interferon-gamma) that affect expression of adhesion molecules, chemokines (IL-8) that direct the influx of white blood cells and endothelins that may exacerbate underlying hypertension and increase shear force-related red blood cell destruction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10573073     DOI: 10.1097/00007890-199911150-00020

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

Review 1.  Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies.

Authors:  J Khosla; A C Yeh; T R Spitzer; B R Dey
Journal:  Bone Marrow Transplant       Date:  2017-10-02       Impact factor: 5.483

2.  The role of endothelial cell injury in thrombotic microangiopathy.

Authors:  Ryan J Goldberg; Takahiko Nakagawa; Richard J Johnson; Joshua M Thurman
Journal:  Am J Kidney Dis       Date:  2010-09-16       Impact factor: 8.860

Review 3.  Relevance of ADAMTS13 to liver transplantation and surgery.

Authors:  Saiho Ko; Hisanao Chisuwa; Masanori Matsumoto; Yoshihiro Fujimura; Eiji Okano; Yoshiyuki Nakajima
Journal:  World J Hepatol       Date:  2015-07-08

4.  Acute graft-versus-host disease increase risk and accuracy in prediction model of transplantation-associated thrombotic microangiopathy in patients with myelodysplastic syndrome.

Authors:  Ziyan Zhang; Hong Wang; Jiaqian Qi; Yaqiong Tang; Chengsen Cai; Meng Zhou; Tingting Pan; Depei Wu; Yue Han
Journal:  Ann Hematol       Date:  2022-03-31       Impact factor: 3.673

Review 5.  Transplant-associated thrombotic microangiopathy: opening Pandora's box.

Authors:  E Gavriilaki; I Sakellari; A Anagnostopoulos; R A Brodsky
Journal:  Bone Marrow Transplant       Date:  2017-03-13       Impact factor: 5.483

Review 6.  Lessons From Pancreas Transplantation in Type 1 Diabetes: Recurrence of Islet Autoimmunity.

Authors:  George W Burke; Francesco Vendrame; Sahil K Virdi; G Ciancio; Linda Chen; Phillip Ruiz; Shari Messinger; Helena K Reijonen; Alberto Pugliese
Journal:  Curr Diab Rep       Date:  2015-12       Impact factor: 4.810

Review 7.  Transplantation for the treatment of type 1 diabetes.

Authors:  R Mark Meloche
Journal:  World J Gastroenterol       Date:  2007-12-21       Impact factor: 5.742

8.  Successful treatment of tacrolimus (FK506)-related leukoencephalopathy with cerebral hemorrhage in a patient who underwent nonmyeloablative stem cell transplantation.

Authors:  Hiroya Tamaki; Manabu Kawakami; Kazuhiro Ikegame; Kenichiro Iio; Yu Harada; Kazuo Hatanaka; Yoshihiro Oka; Ichiro Kawase; Hiroyasu Ogawa
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490

9.  Successful treatment of severe bleeding with recombinant factor VIIa after kidney transplantation.

Authors:  S E M J Gielen-Wijffels; W N K A van Mook; S van der Geest; G Ramsay
Journal:  Intensive Care Med       Date:  2004-02-24       Impact factor: 17.440

10.  Differing tales of two patients after receiving a kidney transplant from a donor with disseminated intravascular coagulation.

Authors:  Pradeep V Kadambi; Ann K Gamilla-Crudo; Mohammad Almiani; Michelle A Josephson; W James Chon
Journal:  Case Rep Transplant       Date:  2014-06-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.